Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Share-based Compensation (2016 - 2025)

Celldex Therapeutics has reported Share-based Compensation over the past 16 years, most recently at $8.9 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $8.9 million for Q4 2025, down 8.91% from a year ago — trailing twelve months through Dec 2025 was $36.2 million (up 5.77% YoY), and the annual figure for FY2025 was $36.2 million, up 5.77%.
  • Share-based Compensation for Q4 2025 was $8.9 million at Celldex Therapeutics, up from $8.8 million in the prior quarter.
  • Over the last five years, Share-based Compensation for CLDX hit a ceiling of $9.8 million in Q4 2024 and a floor of $1.3 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $6.2 million (2023), compared with a mean of $5.9 million.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 149.8% in 2021 and later fell 8.91% in 2025.
  • Celldex Therapeutics' Share-based Compensation stood at $3.1 million in 2021, then soared by 43.57% to $4.5 million in 2022, then skyrocketed by 59.98% to $7.2 million in 2023, then skyrocketed by 35.61% to $9.8 million in 2024, then fell by 8.91% to $8.9 million in 2025.
  • The last three reported values for Share-based Compensation were $8.9 million (Q4 2025), $8.8 million (Q3 2025), and $9.2 million (Q2 2025) per Business Quant data.